Welcome to our dedicated page for Bayer A G news (Ticker: BAYZF), a resource for investors and traders seeking the latest updates and insights on Bayer A G stock.
The BAYZF news page on Stock Titan aggregates recent announcements and press releases related to Bayer AG, a global life science company with core competencies in health care and nutrition. Investors and observers can use this feed to follow how Bayer communicates about its pharmaceutical pipeline, radiology developments, crop science launches and broader corporate strategy.
Recent Bayer news has highlighted updates on its Pharmaceuticals Division, including growth plans built around high-value products and a modality-rich pipeline in oncology, cardiology, neurology, immunology and women’s health. Releases describe pivotal approvals, regulatory milestones, and clinical data from programs in areas such as stroke prevention, heart failure, chronic kidney disease, prostate cancer, lung cancer and menopause-related vasomotor symptoms.
The news flow also covers Bayer’s activities in radiology and molecular imaging, such as clinical results for an investigational low-dose MRI contrast agent and the acquisition of investigational PET and SPECT tracers for diagnosing cardiac amyloidosis. In addition, company communications report collaborations in advanced modalities like cell and gene therapy and siRNA-based treatments, as well as progress in rare kidney diseases including Alport Syndrome.
Beyond human health, Bayer’s crop science releases describe new insecticides and seed treatments for crops such as canola and pulses, illustrating its role in agricultural inputs and food production. Together, these updates provide context on how Bayer pursues its stated mission of “Health for all, Hunger for none” across pharmaceuticals, diagnostics and agriculture. For anyone tracking BAYZF, this news page offers a centralized view of the company’s reported clinical milestones, product launches, partnerships and strategic initiatives over time.
Bayer Group (OTC:BAYRY) is consolidating its U.S. glyphosate business into a distinct entity, Ruveon, based in St. Louis, Missouri. Ruveon will manage U.S. glyphosate pricing, go-to-market strategy, production and logistics while remaining part of Bayer Group.
This move supports the Crop Science division’s Five-Year Framework to enhance growth, resilience and profitability. Dedicated U.S. glyphosate product and commercial teams have joined Ruveon, which will supply Roundup and other glyphosate brands. Alfonso Alba Ordóñez becomes CEO, and Steve Knodle leads commercial business.
Bayer (BAYRY) and Iambic Therapeutics announced a drug discovery collaboration focused on small molecule discovery using Iambic’s AI-driven platform, including Enchant and NeuralPLexer. The partnership targets hard-to-drug targets to enhance Bayer’s early R&D portfolio and pipeline.
Iambic will receive an upfront payment plus potential milestone and royalty payments.
Bayer (OTC:BAYRY) named Kacy Perry as Country Division Head for Crop Science Canada, effective July 1. She will lead 550+ employees across multiple Canadian sites and join the North American Leadership Team.
Perry succeeds Antoine Bernet and brings extensive experience from marketing, product management, and sales leadership roles.
Bayer (OTC:BAYRY) completed the acquisition of Perfuse Therapeutics, fully integrating the company and obtaining full rights to PER-001, an intravitreal implant in Phase II development for Glaucoma and Diabetic Retinopathy.
Bayer paid an upfront USD 300 million, with total potential deal value up to USD 2.45 billion, including success-based milestones. The acquisition is intended to strengthen Bayer’s pharmaceutical pipeline and ophthalmology franchise.
Aleve (OTC:BAYRY) launched its Project DIY campaign under the Feel Aleve platform, featuring HGTV’s Dave and Jenny Marrs and other DIY creators. The initiative highlights Aleve’s claim of up to 12 hours of body pain relief from one dose, helping hobbyists stay focused on home projects.
The campaign began in May and will run through summer 2026 across social, digital, and Walmart retail channels. According to Aleve, 28% of pain relief buyers view home improvement as a hobby, a key insight behind this marketing push.
Bayer (OTC:BAYRY) received FDA approval for AMBELVIST (gadoquatrane), a macrocyclic gadolinium-based contrast agent for contrast-enhanced MRI to detect and visualize lesions with abnormal vascularity in the CNS and non-CNS body regions in adults and pediatric patients, including term neonates.
AMBELVIST is dosed at 0.01 mmol/kg (0.04 mmol Gd/kg), using 60% less gadolinium than mGBCAs at 0.1 mmol Gd/kg and 20% less than gadopiclenol at 0.05 mmol Gd/kg. Phase III QUANTI studies supported efficacy and safety. The product carries a Boxed Warning for intrathecal use and nephrogenic systemic fibrosis and is contraindicated in patients with prior severe hypersensitivity to AMBELVIST.
Bayer (OTC:BAYRY) appointed Dr. Jost Reinhard as President of its Radiology business within the Pharmaceuticals Division, effective August 1, 2026. He will report to Stefan Oelrich and succeeds Nelson Ambrogio, who became President of Bayer U.S. Pharmaceuticals in May 2026.
Reinhard brings over 25 years of healthcare experience at Bayer across R&D, commercial roles in multiple countries, investor relations, and leadership of the Cell and Gene Therapy unit.
Bayer (OTC:BAYRY) announced global Consumer Health leadership changes on June 8, 2026 to support its Road to Billions growth strategy. The moves target faster decisions, stronger commercial execution, and expanded use of data.
New leaders include a global CMO, CDO, CCO, and a new U.S. Consumer Health President.
Bayer (OTC:BAYRY) reported full Phase III FIND-CKD results for KERENDIA (finerenone) in 1,584 adults with non-diabetic chronic kidney disease on standard of care. KERENDIA improved eGFR slope versus placebo (−3.3 vs −4.0 mL/min/1.73 m²/year; difference 0.7; p<0.001) and reduced a composite kidney-cardiovascular outcome (HR 0.77; 95% CI 0.60–0.99; p=0.043). Safety was generally similar, with serious adverse events 20.9% vs 21.2%. Hyperkalemia occurred in 17% vs 13.3%, with serious hyperkalemia <1% in both groups.
Bayer (OTC:BAYRY) will present new investigational data on KERENDIA (finerenone) at the 63rd European Renal Association Congress, June 3‑6, 2026, in Glasgow.
Highlights include first full Phase III FIND‑CKD results in non‑diabetic CKD and initial INFINITY pooled analysis across diabetic and non‑diabetic CKD populations.